Search Results

Vivasure Medical today announced it has treated the first large bore venous patient with the PerQseal ® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device.

Vivasure Medical® today announced it has enrolled the 100th patient in its PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal® Closure Device System.

Vivasure Medical today announced the first patient treated with PerQseal ® Elite, the latest generation of the company’s fully absorbable large-hole closure system.

Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced it has enrolled the first patients in the company’s PerQseal® PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal Closure Device System.

Vivasure Medical ® Limited today announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to advance the company’s PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and effectiveness of the Vivasure PerQseal® Closure Device System.

Vivasure Medical today announced that the first patient was treated in a U.S. early feasibility study evaluating PerQseal.

Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, announced the closing of the first tranche of €22 million as part of its Series D financing round that could reach up to €52 million in total.

Vivasure Medical today announced its development program for PerQseal ® Blue, the company’s new investigational product.